MERGER PURCHASE AGREEMENT
Agreement entered into as of December 14, 1999, by and among Rexall
Sundown, Inc., a Florida corporation (the "Buyer"), RSM Acquisition Corp., a
Delaware corporation and a wholly-owned Subsidiary of the Buyer (the "Transitory
Subsidiary"), the persons set forth on the Schedule of Sellers attached hereto
(collectively the "Sellers") and MET-Rx Nutrition, Inc., a Delaware corporation
(the "Company"). The Buyer, the Transitory Subsidiary, the Sellers and the
Company are referred to collectively herein as the "Parties".
This Agreement contemplates a transaction in which the Buyer will
acquire all of the outstanding capital stock of the Company for cash through a
reverse subsidiary merger of the Transitory Subsidiary with and into the
Company.
Now, therefore, in consideration of the premises and the mutual
promises herein made, and in consideration of the representations, warranties,
and covenants herein contained, the Parties agree as follows.
1. Definitions.
"Adverse Consequences" means all actions, suits, proceedings, hearings,
investigations, charges, complaints, claims, demands, injunctions, judgments,
orders, decrees, rulings, damages, dues, penalties, fines, costs, liabilities,
obligations, taxes, liens, losses, expenses, and fees, including court costs and
reasonable attorney's fees and expenses.
"Affiliate" has the meaning set forth in Rule 12b-2 of the regulations
promulgated under the Securities Exchange Act.
"Allocable Portion" means, with respect to the share of any Seller, in
a particular amount that percentage set forth opposite the Seller's name on the
Schedule of the Allocable Portions.
"Business" has the meaning set forth in Section 6(b) below.
"Buyer" has the meaning set forth in the preface above.
"Certificate of Merger" has the meaning set forth in Section 2(d)
below.
"Closing" has the meaning set forth in Section 2(c) below.
"Closing Date" has the meaning set forth in Section 2(c) below.
"COBRA" means the requirements of Part 6 of Subtitle B of Title I of
ERISA and Code Section 4980B.
"Code" means the Internal Revenue Code of 1986, as amended.
"Common Share" means any share of the Common Stock, par value $.01 per
share, of the Company.
"Company" has the meaning set forth in the preface above.
"Confidential Information" has the meaning ascribed to such term in
that certain confidentiality agreement between Buyer and the Company, dated as
of May 25, 1999.
1
"Contracts" has the meaning set forth in Section 4(p) below.
"CPSC" has the meaning set forth in Section 4(z) below.
"Disclosure Schedule" has the meaning set forth in Section 4 below.
"Effective Time" has the meaning set forth in Section 2(e) below.
"Employee Benefit Plan" means any (a) nonqualified deferred
compensation or retirement plan or arrangement, (b) qualified defined
contribution retirement plan or arrangement which is an Employee Pension Benefit
Plan, (c) qualified defined benefit retirement plan or arrangement which is an
Employee Pension Benefit Plan, or (d) Employee Welfare Benefit Plan.
"Employee Pension Benefit Plan" has the meaning set forth in ERISA
Section 3(2).
"Employee Welfare Benefit Plan" has the meaning set forth in ERISA
Section 3(1).
"Environmental Requirements" shall mean all federal, state and local
statutes, regulations, ordinances concerning pollution or protection of the
environment, including without limitation all those relating to the generation,
handling, transportation, treatment, storage, disposal or cleanup of hazardous
materials or wastes, as such requirements are enacted and in effect on or prior
to the Closing Date.
"ERISA" means the Employee Retirement Income Security Act of 1974, as
amended.
"FDA" has the meaning set forth in Section 4(z) below.
"Financial Statement" has the meaning set forth in Section 4(g) below.
"Foundation" has the meaning set forth in Section 8(c)(ii) below.
"Foundation Litigation" has the meaning set forth in Section 8(c)(i)
below.
"FTC" has the meaning set forth in Section 4(z) below.
"GAAP" means United States generally accepted accounting principles as
in effect from time to time.
"▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Act" means the ▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Antitrust
Improvements Act of 1976, as amended.
"Indebtedness" means interest bearing indebtedness for borrowed money
evidenced by a note, bond, debenture or other debt security.
"Indemnified Party" has the meaning set forth in Section 8(f) below.
"Indemnifying Party" has the meaning set forth in Section 8(f) below.
"Intellectual Property" means patents, invention disclosures,
registered trademarks, trade names, registered copyrights and registered service
marks, and any applications for registration of the foregoing, and any goodwill
associated therewith, domain names and computer software (except for licenses of
commercially available software).
"Knowledge" means, with respect to any statement in this Agreement that
is qualified as to the Knowledge of Sellers, the actual knowledge of the Sellers
2
after reasonable investigation with regard to the particular matters set forth
in such statement or the actual knowledge of the employees of the Company
primarily responsible for the particular matters referred to in such statement.
"Material Adverse Effect" means a material adverse effect on the
business, financial condition, operations, assets or results of operations of
the Company and its Subsidiaries taken as a whole.
"Merger" has the meaning set forth in Section 2(a) below.
"Merger Consideration" has the meaning set forth in Section 2(e) below.
"Most Recent Balance Sheet" means the balance sheet contained within
the Most Recent Financial Statements and attached to the Disclosure Schedule.
"Most Recent Financial Statements" has the meaning set forth in Section
4(g) below.
"Most Recent Fiscal Year End" has the meaning set forth in Section 4(g)
below.
"Ordinary Course of Business" means the ordinary course of business
consistent with the Company's past custom and practice.
"Party" has the meaning set forth in the preface above.
"Person" means an individual, a partnership, a corporation, an
association, a joint stock company, a trust, a joint venture, an unincorporated
organization, or a governmental entity (or any department, agency, or political
subdivision thereof).
"Preferred Share" means any share of the Preferred Stock, par value
$.01 per share, of the Company.
"Purchase Price" has the meaning set forth in Section 2(b) below.
"Recovered Monies" has the meaning set forth in Section 8(c)(i) below.
"Securities Act" means the Securities Act of 1933, as amended.
"Securities Exchange Act" means the Securities Exchange Act of 1934, as
amended.
"Security Interest" means any mortgage, pledge, lien, encumbrance,
charge, or other security interest, other than (a) mechanic's, materialmen's,
and similar liens, (b) liens for taxes not yet due and payable or for taxes that
the taxpayer is contesting in good faith through appropriate proceedings, and
(c) purchase money liens set forth on the Disclosure Schedule and liens securing
rental payments under the capital lease arrangements set forth on the Disclosure
Schedule.
"Seller" has the meaning set forth in the preface above.
"Share" is used to collectively refer to Common Shares and Preferred
Shares.
"S Tax Claim" has the meaning set forth in Section 8(a) below.
"Subsidiary" means any corporation with respect to which a specified
Person (or a Subsidiary thereof) owns a majority of the common stock or has the
power to vote or direct the voting of sufficient securities to elect a majority
of the directors.
"Surviving Corporation" has the meaning set forth in Section 2(a)
below.
3
"Tax" means any federal, state, local, or foreign tax with respect to
the income, business, operations, or properties of the Company and its
Subsidiaries, including any interest, penalty, or addition thereto, whether
disputed or not.
"Tax Return" means any return, declaration, report, claim for refund,
or information return or statement relating to Taxes, including any schedule or
attachment thereto, and including any amendment thereof.
"Territory" has the meaning set forth in Section 6(b) below.
"Third Party Claim" has the meaning set forth in Section 8(f) below.
"Transitory Subsidiary" has the meaning set forth in the preface above.
"USDA" has the meaning set forth in Section 4(z) below.
2. Basic Transaction.
(a) The Merger. On and subject to the terms and conditions of this
Agreement, the Transitory Subsidiary will merge with and into the Company (the
"Merger") at the Effective Time. The Company shall be the corporation surviving
the Merger (the "Surviving Corporation").
(b) Purchase Price.
(i) In consideration of the Merger, the Buyer agrees to pay
the aggregate Purchase Price in accordance with the provisions of
Section 2(f) below.
(ii) The term "Purchase Price" shall mean $77,500,000.
(c) The Closing. The closing of the transactions contemplated by this
Agreement (the "Closing") shall take place at the offices of ▇▇▇▇▇▇▇▇ & ▇▇▇▇▇ at
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇, commencing at 9:00
a.m. local time on the second business day following the satisfaction or waiver
of all conditions to the obligations of the Parties to consummate the
transactions contemplated hereby (other than conditions with respect to actions
the respective Parties will take at the Closing itself) or such other date as
the Buyer and the Sellers may mutually determine (the "Closing Date").
(d) Actions at the Closing. At the Closing, (i) the Company will
deliver to the Buyer and the Transitory Subsidiary the various certificates,
instruments, and documents referred to in Section 7(a) below, (ii) the Buyer and
the Transitory Subsidiary will deliver to the Company the various certificates,
instruments, and documents referred to in Section 7(b) below, (iii) the Company
and the Transitory Subsidiary will file with the Secretary of State of the State
of Delaware a Certificate of Merger (the "Certificate of Merger"), and (iv) the
Buyer will cause the Surviving Corporation to deliver the Purchase Price in the
manner provided below in Section 2(f).
(e) Effect of Merger.
(i) General. The Merger shall become effective at the time (the
"Effective Time") the Company and the Transitory Subsidiary file the
Certificate of Merger with the Secretary of State of the State of
Delaware. The Merger shall have the effect set forth in the Delaware
General Corporation Law. The Surviving Corporation may, at any time
after the Effective Time, take any action (including executing and
4
delivering any document) in the name and on behalf of either the
Company or the Transitory Subsidiary in order to carry out and effect
the transactions contemplated by this Agreement.
(ii) Certificate of Incorporation. The Certificate of
Incorporation of the Surviving Corporation shall be amended and
restated at and as of the Effective Time to read as did the Certificate
of Incorporation of the Transitory Subsidiary immediately prior to the
Effective Time (except that the name of the Surviving Corporation will
remain unchanged).
(iii) Bylaws. The Bylaws of the Surviving Corporation shall be
amended and restated at and as of the Effective Time to read as did the
Bylaws of the Transitory Subsidiary immediately prior to the Effective
Time (except that the name of the Surviving Corporation will remain
unchanged.)
(iv) Directors and Officers. The directors and officers of the
Company shall be the initial directors and officers of the Surviving
Corporation at and as of the Effective Time (retaining their respective
positions and terms of office). Nothing contained in the preceding
sentence shall prohibit or limit the right of the Buyer to replace any
of such directors and officers upon consummation of the transactions
contemplated hereby.
(v) Conversion of Shares. At and as of the Effective Time, (A)
each Common Share shall be converted into the right to receive an
amount equal to a portion of the Purchase Price set forth on the
Schedule of the Purchase Price Allocation attached hereto, (B) each
Preferred Share designated as "Senior Preferred" shall be converted
into the right to receive an amount equal to a portion of the Purchase
Price set forth on the Schedule of the Purchase Price Allocation
attached hereto, and (C) each Preferred Share designated as "Junior
Preferred" shall be converted into the right to receive an amount equal
to a portion of the Purchase Price set forth on the Schedule of the
Purchase Price Allocation attached hereto (such amounts referred to in
clauses (A), (B) and (C) above are referred to herein as the "Merger
Consideration"). No Share shall be deemed to be outstanding or to have
any rights other than those set forth above in this Section 2(e)(v)
after the Effective Time.
(vi) Conversion of Capital Stock of the Transitory Subsidiary. At
and as of the Effective Time, each share of Common Stock, $.01 par
value per share, of the Transitory Subsidiary shall be converted into
one share of Common Stock, $.01 par value per share, of the Surviving
Corporation.
(f) Procedure for Payment. As of the Effective Time, the Buyer will
make full payment of the Merger Consideration to the holders of all of the
outstanding Shares in accordance with the Schedule of the Purchase Price
Allocation against the surrender of the Shares of such holders.
(g) Closing of Transfer Records. After the close of business on the
Closing Date, transfers of Shares outstanding prior to the Effective Time shall
not be made on the stock transfer books of the Surviving Corporation.
3. Representations and Warranties Concerning the Buyer and the
Transitory Subsidiary. Each of the Buyer and the Transitory Subsidiary
represents and warrants to the Company and the Sellers that the statements
contained in this Section 3 are correct and complete as of the date of this
Agreement.
(a) Organization . Each of the Buyer and the Transitory Subsidiary is a
corporation duly organized, validly existing, and in good standing under the
laws of the jurisdiction of its incorporation.
(b) Authorization of Transaction. Each of the Buyer and the Transitory
Subsidiary has full power and authority (including full corporate power and
authority) to execute and deliver this Agreement and to perform its obligations
5
hereunder. This Agreement constitutes the valid and legally binding obligation
of each of the Buyer and the Transitory Subsidiary, enforceable against the
Buyer and the Transitory Subsidiary in accordance with its terms and conditions.
Neither the Buyer nor the Transitory Subsidiary need give any notice to, make
any filing with, or obtain any authorization, consent, or approval of any
government or governmental agency in order to consummate the transactions
contemplated by this Agreement, other than those required under
▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Act.
(c) Noncontravention. Neither the execution and the delivery of this
Agreement, nor the consummation of the transactions contemplated hereby, will
violate any constitution, statute, regulation, rule, injunction, judgment,
order, decree, ruling, charge, or other restriction of any government,
governmental agency, or court to which either the Buyer or the Transitory
Subsidiary is subject or any provision of their charter or bylaws.
(d) Brokers' Fees. Neither the Buyer nor the Transitory Subsidiary has
any liability or obligation to pay any fees or commissions to any broker,
finder, or agent with respect to the transactions contemplated by this Agreement
for which any of the Company and its Subsidiaries or any Seller could become
liable or obligated.
(e) Financing. At the Closing, the Buyer shall have sufficient cash,
available lines of credit or other sources of immediately available funds to
enable it to pay at the Closing to the holders of all outstanding Shares at the
Closing the Purchase Price and pay any other amounts to be paid by it hereunder.
4. Representations and Warranties Concerning the Company and Its
Subsidiaries. Each of the Sellers, jointly but not severally, represents and
warrants to the Buyer and the Transitory Subsidiary that the statements
contained in this Section 4 are correct and complete as of the date of this
Agreement to his or its Knowledge (except that such statements in Section 4(a),
Section 4(b), and Section 4(d) are not qualified by such Knowledge), except as
set forth in the disclosure schedule attached hereto (the "Disclosure
Schedule").
(a) Organization, Qualification, and Corporate Power. Each of the
Company and its Subsidiaries is a corporation duly organized, validly existing,
and in good standing under the laws of the jurisdiction of its incorporation.
Each of the Company and its Subsidiaries is duly authorized to conduct business
and is in good standing under the laws of each jurisdiction where such
qualification is required, except where the lack of such qualification would not
have a Material Adverse Effect. Each of the Company and its Subsidiaries has
full corporate power and authority to carry on the businesses in which it is
engaged and to own and use the properties owned and used by it.
(b) Capitalization. The entire authorized capital stock of the Company
consists of (i) 20,000,000 Common Shares, of which (A) 10,000,000 shares have
been designated "Series A," of which 900,000 shares are issued and outstanding
as of the date of this Agreement, and (B) 10,000,000 shares have been designated
"Series B," of which 75,000 shares are issued and outstanding as of the date of
this Agreement, and (ii) 100,000 Preferred Shares, of which (A) 50,000 shares
have been designated "Senior Preferred," of which 21,400.9433 shares are issued
and outstanding as of the date of this Agreement, and (B) 50,000 shares have
been designated "Junior Preferred," of which 1,000 shares are issued and
outstanding as of the date of this Agreement. All of the issued and outstanding
Shares have been duly authorized, are validly issued, fully paid, and
nonassessable, are held of record by the respective stockholders as set forth in
Section 4(b) of the Disclosure Schedule, and are free and clear of any and all
Security Interests or other restrictions or limitations whatsoever. None of the
issued and outstanding Shares were issued in violation of (i) any preemptive or
other rights of any person to acquire securities of the Company, or (ii) any
applicable federal or state securities laws, and the rules and regulations
promulgated thereunder. There are no outstanding or authorized options,
warrants, purchase rights, subscription rights, conversion rights, exchange
rights, or other contracts or commitments that could require the Company to
issue, sell, or otherwise cause to become outstanding any of its capital stock.
(c) Noncontravention. Neither the execution and the delivery of this
Agreement, nor the consummation of the transactions contemplated hereby, will
6
(i) violate any constitution, statute, regulation, rule, injunction, judgment,
order, decree, ruling, charge, or other restriction of any government,
governmental agency, or court to which any of the Company and its Subsidiaries
is subject, (ii) violate any provision of the charter or bylaws of any of the
Company and its Subsidiaries or (iii) conflict with, result in a breach of,
constitute a default under, result in the acceleration of, create in any party
the right to accelerate, terminate, modify, or cancel, or require any notice
under any agreement, contract, lease, license, instrument, or other arrangement
to which any of the Company and its Subsidiaries is a party or by which it is
bound or to which any of its assets is subject (or result in the imposition of
any Security Interest upon any of its assets), except, in the case of each of
clauses (i) and (iii) above, where the violation, conflict, breach, default,
acceleration, termination, modification, cancellation, failure to give notice,
or Security Interest would not have a Material Adverse Effect or materially
affect the ability of the Parties to consummate the transactions contemplated by
this Agreement. None of the Company and its Subsidiaries needs to give any
notice to, make any filing with, or obtain any authorization, consent, or
approval of any government or governmental agency in order for the Parties to
consummate the transactions contemplated by this Agreement, other than those
required under ▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Act and except where the failure to give
notice, to file, or to obtain any authorization, consent, or approval would not
have a Material Adverse Effect or materially affect the ability of the Parties
to consummate the transactions contemplated by this Agreement.
(d) Brokers' Fees. None of the Company and its Subsidiaries has any
liability or obligation to pay any fees or commissions to any broker, finder, or
agent with respect to the transactions contemplated by this Agreement, other
than such liability or obligation to Lazard Freres & Co. LLC and ▇▇▇▇▇▇▇▇▇,
▇▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ or their Affiliates.
(e) Title to Tangible Assets. The Company and its Subsidiaries have
good title to, or a valid leasehold interest in, the tangible assets they use
regularly in the conduct of their businesses, free and clear of all Security
Interests.
(f) Subsidiaries. Section 4(f) of the Disclosure Schedule sets forth
for each Subsidiary of the Company (i) its name and jurisdiction of
incorporation, together with each jurisdiction in which it is required to be
qualified to do business, except where the lack of such qualification would not
have a Material Adverse Effect, (ii) the number of shares of authorized capital
stock of each class of its capital stock, (iii) the number of issued and
outstanding shares of each class of its capital stock, the names of the holders
thereof, and the number of shares held by each such holder, and (iv) the number
of shares of its capital stock held in treasury. All of the issued and
outstanding shares of capital stock of each Subsidiary of the Company have been
duly authorized and are validly issued, free of preemptive rights, fully paid,
and nonassessable. One of the Company or its Subsidiaries holds of record and
owns beneficially all of the outstanding shares of each Subsidiary of the
Company, free and clear of any restrictions on transfer (other than restrictions
under the Securities Act and state securities laws), taxes, Security Interests,
options, warrants, purchase rights, contracts, commitments, equities, claims,
and demands. There are no outstanding or authorized options, warrants, purchase
rights, subscription rights, conversion rights, exchange rights, or other
contracts or commitments that could require any Subsidiary to issue, sell, or
otherwise cause to become outstanding any of its capital stock.
(g) Financial Statements. Attached to Section 4(g) of the Disclosure
Schedule are the following financial statements (collectively the "Financial
Statements"): (i) audited consolidated balance sheet and statement of income,
changes in stockholders' equity, and cash flow as of and for the fiscal year
ended December 31, 1998 (the "Most Recent Fiscal Year End") for the Company and
its Subsidiaries; and (ii) unaudited consolidated balance sheet and statement of
income, changes in stockholders' equity, and cash flow (the "Most Recent
Financial Statements") as of and for the ten months ended October 31, 1999 for
the Company and its Subsidiaries. The Financial Statements (including the notes
thereto) have been prepared in accordance with GAAP applied on a consistent
basis throughout the periods covered thereby and present fairly the financial
condition of the Company and its Subsidiaries as of such dates and the results
of operations of the Company and its Subsidiaries for such periods; provided,
however, that the Most Recent Financial Statements lack footnotes and other
7
presentation items and are subject to normal year-end adjustments in accordance
with the Ordinary Course of Business consistent with past practice, none of
which will, either individually or in the aggregate, have a Material Adverse
Effect.
(h) Events Subsequent to Most Recent Fiscal Year End. Since the Most
Recent Fiscal Year End, there has not been any Material Adverse Effect, and
neither the Company nor any of its Subsidiaries has since that date:
(i) sold, leased, transferred, or assigned any asset outside of
the Ordinary Course of Business;
(ii) made any expenditure outside the Ordinary Course of
Business;
(iii) made any capital investment in, or any material loan to,
any other Person outside the Ordinary Course of Business;
(iv) amended or authorized the amendment of its charter or
bylaws;
(v) issued, sold, or otherwise disposed of any of its capital
stock, or granted any options, warrants or other rights to purchase or
obtain (including upon conversion, exchange, or exercise) any of its
capital stock;
(vi) declared, set aside, or paid any dividend or made any
distribution with respect to its capital stock (whether in cash or in
kind) or redeemed, purchased, or otherwise acquired any of its capital
stock;
(vii) made any loan or advance to any Person outside the Ordinary
Course of Business;
(viii) entered into any transaction with, any of its directors,
officers, employees or stockholders outside the Ordinary Course of
Business;
(ix) entered into any employment contract or collective
bargaining agreement or modified the terms of any existing such
contract or agreement;
(x) granted any increase in the base compensation of any of its
directors, officers, and employees outside the Ordinary Course of
Business;
(xi) adopted, amended, modified, or terminated any bonus,
profit-sharing, incentive, severance, or other plan, contract, or
commitment for the benefit of any of its directors, officers, and
employees (or taken any such action with respect to any other Employee
Benefit Plan);
(xii) made any other change in employment terms for any of its
directors, officers, and employees outside the Ordinary Course of
Business; or
(xiii) committed to any of the foregoing.
(i) Undisclosed Liabilities. None of the Company and its Subsidiaries
has any liability (whether known or unknown, whether asserted or unasserted,
whether absolute or contingent, whether accrued or unaccrued, whether liquidated
or unliquidated, and whether due or to become due, including any liability for
taxes) of the type which should be reflected in balance sheets prepared in
accordance with GAAP, except for (i) liabilities set forth on the balance sheet
for the Most Recent Fiscal Year End and in any notes thereto and (ii)
liabilities which have arisen after the Most Recent Fiscal Year End in the
Ordinary Course of Business or in connection with the transactions contemplated
hereby.
8
(j) Legal Compliance. (i) Each of the Company and its Subsidiaries has
complied in all material respects with all applicable laws (including rules,
regulations, codes, plans, injunctions, judgments, orders, decrees, rulings, and
charges thereunder) of federal, state, local, and foreign governments (and all
agencies thereof), and (ii) no action, suit, proceeding, hearing, investigation,
charge, complaint, claim, demand, or notice has been filed or commenced against
any of them alleging any failure so to comply.
(k) Tax Matters.
(i) Each of the Company and its Subsidiaries has filed all Tax
Returns that it was required to file, and has paid all Taxes shown
thereon as owing.
(ii) There is no material dispute or claim pending or threatened
concerning any Tax liability of any of the Company and its
Subsidiaries.
(iii) Section 4(k) of the Disclosure Schedule lists all income
Tax Returns filed with respect to any of the Company and its
Subsidiaries for taxable periods ended on or after December 31, 1996,
indicates those income Tax Returns that have been audited, and
indicates those income Tax Returns that currently are the subject of
audit. The Company has delivered to the Buyer correct and complete
copies of all federal income Tax Returns, examination reports, and
statements of deficiencies assessed against, or agreed to by any of the
Company and its Subsidiaries since December 31, 1996.
(iv) None of the Company and its Subsidiaries has waived any
statute of limitations in respect of Taxes or agreed to any extension
of time with respect to a Tax assessment or deficiency.
(l) Real Property.
(i) The Company and its Subsidiaries own no real property other
than tenant improvements.
(ii) Section 4(l)(ii) of the Disclosure Schedule lists and
describes briefly all real property leased or subleased to any of the
Company and its Subsidiaries. The Company has delivered to the Buyer
correct and complete copies of the leases and subleases listed in
Section 4(l)(ii) of the Disclosure Schedule. Each lease and sublease
listed in Section 4(l)(ii) of the Disclosure Schedule is legal, valid,
binding, enforceable, and in full force and effect.
(m) Intellectual Property.
(i) Section 4(m)(i) of the Disclosure Schedule identifies each
material foreign and domestic patent or registration which has been
issued to any of the Company and its Subsidiaries with respect to any
of its Intellectual Property, identifies each pending material foreign
and domestic patent application or application for registration which
any of the Company and its Subsidiaries has made with respect to any of
its Intellectual Property, and identifies each material license,
agreement, or other permission which any of the Company and its
Subsidiaries has granted to any third party with respect to any of its
Intellectual Property. To the extent that any item identified in
Section 4(m)(i) of the Disclosure Schedule has been registered with,
filed in or issued by, any governmental authority, such registrations,
filings or issuances were duly made and remain in full force and
effect. Section 4(m)(i) of the Disclosure Schedule also identifies each
material trade name, material unregistered trademark or service ▇▇▇▇ or
material copyright used by any of the Company and its Subsidiaries in
connection with any of their businesses. The Intellectual Property
9
identified on Section 4(m)(i) of the Disclosure Schedule has not been
licensed, sub-licensed or assigned by the Company and its Subsidiaries
to any third party other than the Buyer pursuant to this Agreement. The
Company and its Subsidiaries possess all right, title, and interest in
and to or have the right to use each item of Intellectual Property
identified in Section 4(m)(i) of the Disclosure Schedule and shall as
of the Closing Date possess all right, title and interest in such
Intellectual Property, free and clear of any Security Interest,
license, or other restriction, except where the failure to possess such
right, title and interest as such would not have a Material Adverse
Effect. In addition, there have been no claims received by the Company
and its Subsidiaries asserting the invalidity, misuse or
unenforceability of the Intellectual Property identified on Section
4(m)(i) of the Disclosure Schedule and no grounds for any such claims
exist.
(ii) Section 4(m)(ii) of the Disclosure Schedule identifies each
license, sublicense, agreement, or permission pursuant to which the
Company or any of its Subsidiaries uses the Intellectual Property of
any third party. Each license, sublicense, agreement, or permission
identified in Section 4(m)(ii) of the Disclosure Schedule is legal,
valid, binding, enforceable, and in full force and effect, except where
the illegality, invalidity, nonbinding nature, unenforceability, or
ineffectiveness would not have a Material Adverse Effect.
(iii) Neither the operation of the Company's and each
Subsidiary's business nor the Intellectual Property identified in
Section 4(m)(i) and Section 4(m)(ii) of the Disclosure Schedule and
which is material to the operations of the Company and its Subsidiaries
has interfered with, infringed upon, misappropriated, or violated any
Intellectual Property rights of third parties, and none of the Sellers
or directors or officers of the Company or its Subsidiaries has ever
received any claim, charge or complaint alleging any such interference,
infringements, misappropriation, or violation (including any claim that
any of the Company and its Subsidiaries must license or refrain from
using any Intellectual Property rights of any third party), except for
such infringements, misappropriations, or violations that would not
have a Material Adverse Effect. No third party has interfered with,
infringed upon, misappropriated, or violated any Intellectual Property
rights identified in Section 4(m)(i) and Section 4(m)(ii) of the
Disclosure Schedule, except for such infringements, misappropriations,
or violations that would not have a Material Adverse Effect.
(iv) The Intellectual Property identified in Section 4(m)(i) and
Section 4(m)(ii) of the Disclosure Schedule is sufficient and includes
all the Intellectual Property necessary for the Company and its
Subsidiaries to conduct their businesses as presently being conducted.
(v) There has not been any failure to act by the Company and its
Subsidiaries during the prosecution or registration of, or any
proceeding relating to, any of the Intellectual Property identified in
Section 4(m)(i) or Section 4(m)(ii) of the Disclosure Schedule that
could render invalid or unenforceable, or negate the right to the
issuance of any such Intellectual Property.
(vi) To the extent that any of the Intellectual Property
identified in Section 4(m)(i) or Section 4(m)(ii) of the Disclosure
Schedule constitutes proprietary or confidential information, the
Company and its Subsidiaries have adequately safeguarded such
information from disclosure.
(vii) Under the specific written terms of any Intellectual
Property or agreements with respect to Intellectual Property identified
in Section 4(m)(i) and Section 4(m)(ii) of the Disclosure Schedule, no
consent is necessary to consummate the reverse triangular merger
contemplated by this Agreement or assign such agreements.
(n) Tangible Assets. The buildings, machinery, equipment, and other
tangible assets that the Company and its Subsidiaries own and lease include all
tangible assets necessary for the Company and its Subsidiaries to conduct their
businesses as presently conducted, are suitable for the purposes for which they
are presently used, are free from material defects (patent and latent), have
been maintained in accordance with normal industry practice, are in good
operating condition and repair (subject to normal wear and tear), and are free
and clear of all Security Interests.
10
(o) Inventory. The inventory of the Company and its Subsidiaries
consists of raw materials and supplies, manufactured and processed parts, work
in process, and finished goods, all of which is merchantable and fit for the
purpose for which it was procured or manufactured, subject to a reserve for
inventory in accordance with GAAP and the past custom and practice of the
Company and its Subsidiaries, and is free and clear of all Security Interests.
(p) Contracts. Section 4(p) of the Disclosure Schedule lists all
written contracts and other written agreements to which any of the Company and
its Subsidiaries is a party the performance of which involves consideration in
excess of $100,000 in any twelve-month period and are not cancellable by the
Company or any of its Subsidiaries, as the case may be, on less than ninety days
notice without penalty to the Company or its Subsidiaries (the "Contracts"). The
Company has delivered to the Buyer a correct and complete copy of each such
Contract listed in Section 4(p) of the Disclosure Schedule. With respect to each
such Contract: (A) the Contract is legal, valid, binding, enforceable, and in
full force and effect in all material respects; (B) neither the Company nor any
of its Subsidiaries is in material breach or default thereof; (C) no event has
occurred which with notice or lapse of time would constitute a material breach
or default, or permit termination, modification or acceleration, under the
Contract; and (D) no consent is necessary by the terms of the Contract to
consummate the reverse triangular merger contemplated by this Agreement in order
to provide the Buyer with the benefit of such Contract.
(q) Notes and Accounts Receivable. All notes and accounts receivable of
the Company and its Subsidiaries are reflected properly on their books and
records in accordance with GAAP, are valid receivables, are current and
collectible in accordance with their terms, subject to a reserve for bad debts
in accordance with the past custom and practice of the Company and its
Subsidiaries.
(r) Insurance. Section 4(r) of the Disclosure Schedule sets forth the
following information with respect to each insurance policy (including policies
providing property, casualty, liability, and workers' compensation coverage and
bond and surety arrangements) with respect to which any of the Company and its
Subsidiaries is a party, a named insured, or otherwise the beneficiary of
coverage:
(i) the name, address, and telephone number of the agent;
(ii) the name of the insurer, the name of the policyholder, and
the name of each covered insured;
(iii) the policy number and the period of coverage; and
(iv) the scope and amount of coverage.
All such policies are in full force and effect with all premiums due
thereupon paid.
(s) Litigation. Section 4(s) of the Disclosure Schedule sets forth each
instance in which any of the Company and its Subsidiaries (i) is subject to any
outstanding, threatened injunction, judgment, order, decree, ruling, or charge
or (ii) is a party to any pending, threatened action, suit, proceeding, hearing,
or investigation of, in, or before any court or quasi-judicial or administrative
agency of any federal, state, local, or foreign jurisdiction.
(t) Employees. None of the Company and its Subsidiaries is a party to
or bound by any collective bargaining agreement, nor has any of them experienced
any strike or material grievance, material claim of unfair labor practices, or
other collective bargaining dispute within the past three years. There is no
organizational effort presently being made or threatened by or on behalf of any
labor union with respect to employees of any of the Company and its
Subsidiaries.
11
(u) Employee Benefits.
(i) Section 4(u) of the Disclosure Schedule lists each Employee
Benefit Plan that any of the Company and its Subsidiaries maintains or
to which any of the Company and its Subsidiaries contributes.
(ii) Each such Employee Benefit Plan (and each related trust,
insurance contract, or fund) complies in form and in operation in all
respects with the applicable requirements of ERISA, the Code, and other
applicable laws, except where the failure to comply would not have a
Material Adverse Effect.
(iii) All contributions (including all employer contributions and
employee salary reduction contributions) which are due have been paid
to each such Employee Benefit Plan which is an Employee Pension Benefit
Plan.
(iv) Each such Employee Benefit Plan which is an Employee Pension
Benefit Plan has received a determination letter from the Internal
Revenue Service to the effect that it meets the requirements of Code
Section 401(a) or will file within the remedial amendment period for
such favorable determination letter.
(v) Each such Employee Benefit Plan which is an Employee Pension
Benefit Plan has no funding deficiencies.
(vi) The Company has delivered to the Buyer correct and complete
copies of the plan documents and summary plan descriptions, the most
recent determination letter received from the Internal Revenue Service,
the most recent Form 5500 Annual Report, and all related trust
agreements, insurance contracts, and other funding agreements which
implement each such Employee Benefit Plan.
(v) Environmental Matters.
(i) The Company and its Subsidiaries are in compliance with
Environmental Requirements, except for such noncompliance as would not
have a Material Adverse Effect.
(ii) The Company and its Subsidiaries have not received any
notice regarding any material violation of Environmental Requirements,
or any material liabilities under Environmental Requirements, the
subject of which would have a Material Adverse Effect.
(iii) This Section 4(v) contains the sole and exclusive
representations and warranties of the Sellers with respect to any
environmental, health, or safety matters, including, without
limitation, any arising under any Environmental Requirements.
(w) Certain Business Relationships With the Company and Its
Subsidiaries. None of the Sellers and their Affiliates has been involved in any
business arrangement or relationship with any of the Company and its
Subsidiaries within the past 12 months, and none of the Sellers and their
Affiliates owns any asset, tangible or intangible, which is used in the business
of any of the Company and its Subsidiaries.
(x) Suppliers and Customers. The Company and its Subsidiaries maintain
good relations with all their material suppliers and material customers as well
as with governments, partners, financing sources, and other parties with whom
the Company and its Subsidiaries have relations, and no such party has canceled,
terminated or made any threat to the Company and its Subsidiaries to cancel or
otherwise terminate its relationship with the Company and its Subsidiaries or to
materially decrease its services or supplies to the Company and its Subsidiaries
or its direct or indirect purchase or usage of the products or services of the
Company and its Subsidiaries.
12
(y) Products and Services.
(i) Section 4(y) of the Disclosure Schedule sets forth (A) a list
of all products of the Company and its Subsidiaries which at any time
have been recalled, withdrawn, suspended, or seized by the Company and
its Subsidiaries, whether voluntarily or otherwise, including the date
recalled, withdrawn, suspended, or seized and (B) a brief description
of all completed or pending proceedings seeking the recall, withdrawal,
suspension, or seizure of any product of the Company and its
Subsidiaries.
(ii) There exists no set of facts which would reasonably be
expected to furnish a basis for the recall, withdrawal, suspension, or
seizure of any product registration, product license, repair or
overhaul license, manufacturing license, wholesale dealers license,
export license, or other license, approval, or consent of any
governmental or regulatory authority with respect to the Company and
its Subsidiaries or any of the products of the Company and its
Subsidiaries.
(z) Regulatory Compliance. The Company and its Subsidiaries have
received approval of all registrations, applications, licenses, requests for
exemptions, permits, and other regulatory authorizations necessary for the
conduct of the business of the Company and its Subsidiaries as they are now
conducted with the United States Food and Drug Administration ("FDA"), the
Federal Trade Commission ("FTC"), the Consumer Products Safety Commission
("CPSC"), and the United States Department of Agriculture ("USDA"), as
applicable, except for such registrations, applications, licenses, requests for
exemptions, permits, and other regulatory authorizations of which the failure to
so obtain would not have a Material Adverse Effect. The Company and its
Subsidiaries are in compliance in all respects with all such registrations,
applications, licenses, requests for exemptions, permits, and other regulatory
authorizations, and all applicable FDA, FTC, CPSC, USDA, federal, state and
local rules and regulations, except where the failure to so comply would not
have a Material Adverse Effect.
(aa) Year 2000 Compliance. The Company and its Subsidiaries have
reviewed the areas within their business and operations which could be adversely
affected by, and have developed a program to address on a timely basis, the
"Year 2000 Problem" (that is, the risk that computer applications used by the
Company and its Subsidiaries may be unable to recognize and perform properly
date-sensitive functions involving certain dates prior to and any date on or
after December 31, 1999) and have made related appropriate inquiry of all their
material suppliers and vendors. Based on such review and program, the Company
believes that the "Year 2000 Problem" will not have a Material Adverse Effect.
(bb) Absence of Certain Business Practices. None of the Company, any of
its Subsidiaries, nor any Seller nor any other affiliate or agent of the
Company, nor any other Person acting on behalf of or associated with the
Company, acting alone or together has (i) received, directly or indirectly, any
rebates, payments, commissions, promotional allowances or any other economic
benefits, regardless of their nature or type, from any customer, supplier or
employee or agent of any customer or supplier or (ii) directly or indirectly,
given or agreed to give any money, gift or similar benefit to any customer,
supplier or employee or agent of any customer or supplier, or other Person who
was, is or may be in a position to help or hinder the business of the Company
(or assist the Company in connection with any actual or proposed transaction)
which (A) may subject the Company to any damage or penalty in any civil,
criminal or governmental litigation or proceeding, (B) if not given in the past,
may have had a Material Adverse Effect or (C) if not continued in the future,
would result in a Material Adverse Effect.
5 Pre-Closing Covenants. The Parties agree as follows with respect to
the period between the execution of this Agreement and the Closing.
(a) General. Each of the Parties will use his or its commercially
reasonable efforts to take all action and to do all things necessary, proper, or
13
advisable in order to consummate and make effective the transactions
contemplated by this Agreement (including satisfaction, but not waiver, of the
closing conditions set forth in Section 7 below).
(b) Notices and Consents. Each of the Company and its Subsidiaries will
give any notices to third parties, and each of the Company and its Subsidiaries
will use its commercially reasonable efforts to obtain any third party consents,
that the Buyer reasonably may request in connection with the matters referred to
in Section 4(c) and Section 4(p)above. Each of the Parties will give any notices
to, make any filings with, and use its commercially reasonable efforts to obtain
any authorizations, consents, and approvals of governments and governmental
agencies in connection with the matters referred to in Section 3(b) and Section
4(c) above. Without limiting the generality of the foregoing, each of the
Parties will file any Notification and Report Forms and related material that he
or it may be required to file with the Federal Trade Commission and the
Antitrust Division of the United States Department of Justice under the
▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Act, will use his or its reasonable best efforts to obtain a
waiver from the applicable waiting period, and will make any further filings
pursuant thereto that may be necessary, proper, or advisable in connection
therewith. Buyer and the Company shall share equally the filing fees for any
filings required under the ▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Act.
(c) Operation of BusineSection The Company shall provide daily "flash
reports" in accordance with the Company's current practice and custom to Buyer.
Except as otherwise contemplated herein, the Company and its Subsidiaries shall
conduct their businesses in the Ordinary Course of BusineSection Without
limiting the generality of the foregoing and except as otherwise contemplated in
this section, the Company and its Subsidiaries will not engage in any practice,
take any action, or enter into any transaction of the sort described in Section
4(h) above; provided, however, that the Company and its Subsidiaries may take
the actions necessary to issue Preferred Shares to certain Sellers as
consideration for the payment of certain litigation expenses of the Company by
such Sellers under an agreement with such Sellers as identified on Section 4(b)
of the Disclosure Schedule; provided, further, that the Company and its
Subsidiaries may engage in any such practice, take any action, or enter into any
transactions of the sort described in Section 4(h) with the written consent of
the Buyer (and the Buyer hereby agrees to respond within 5 business days to the
Company and its Subsidiaries' written request to engage in any such practice,
take any action, or enter into any such transaction), which consent may be
withheld in Buyer's sole discretion. In addition, except as otherwise
contemplated in this section, without the prior written consent of Buyer (and
the Buyer hereby agrees to respond within 5 business days to the Company and its
Subsidiaries' written request to engage in any such practice, take any action,
or enter into any such transaction), which consent may be withheld in Buyer's
sole discretion, the Company shall not:
(i) merge into or with or consolidate with, any other
corporation or acquire the business or assets of any Person;
(ii) purchase any securities of any person;
(iii) create, incur, assume, guarantee or otherwise become
liable or obligated with respect to any indebtedness, or make any loan
or advance to, or any investment in, any Person, except in each case in
the Ordinary Course of Business;
(iv) make any change in any existing election, or make any new
election, with respect to any Tax law in any jurisdiction which
election could have an effect on the Tax treatment of the Company or
the Company's business operations;
(v) enter into, amend or terminate any contract or agreement
to which any of the Company or its Subsidiaries is a party the
performance of which involves consideration in excess of $15,000 (or
$50,000 if the Closing has not occurred by January 15) or the duration
of which is greater than one year, except for purchase orders entered
into in the Ordinary Course of Business;
14
(vi) settle any material claim or litigation, or file any
material motions, orders, briefs or settlement agreements in any
proceeding before any governmental authority or any arbitrator, other
than in connection with those matters described in sections I, II, III
and IV of Section 4(s) of the Disclosure Schedule (provided, however,
to the extent there is a monetary settlement of any of the matters
described in sections I, II, III and IV of Section 4(s) of the
Disclosure Schedule prior to the Closing, there shall be a reduction in
the Purchase Price by the amount of any such settlement);
(vii) adopt any Employee Benefit Plan, or grant any increase
in the compensation payable or to become payable to directors or
officers (including, without limitation, any such increase pursuant to
any bonus, profit-sharing or other plan or commitment);
(viii) declare, set aside or pay any dividend or other
distribution (whether in cash, stock or other property) with respect to
its capital stock;
(ix) apply any of its assets to the direct or indirect
payment, prepayment, discharge, satisfaction or reduction of any amount
payable, directly or indirectly, to or for the benefit of any Seller or
any other affiliate of the Company (except for salary and benefits as
currently in effect and except in accordance with existing agreements
and arrangements which have been disclosed to the other parties hereto
in writing), other than in connection with sales of the Company's
products to Club MET-Rx;
(x) enter into any transaction or make any commitment which
could result in any of the representations, warranties or covenants of
the Company and/or Sellers set forth herein not being true and correct
in all material respects after the occurrence of such transaction or
event;
(xi) amend it charter or bylaws;
(xii) issue any capital stock or other securities, or grant,
or enter into any agreement to grant, any options, convertible rights,
other rights, warrants, calls or agreements relating to its securities,
other than in connection with the issuances of Preferred Shares to
certain Sellers as consideration for the payment of certain litigation
expenses of the Company by such Sellers under an agreement with such
Sellers as identified on Section 4(b) of the Disclosure Schedule;
(xiii) pay out any amounts to any participants under the
Company's stock appreciation program; or
(xiv) commit to do any of the foregoing.
(d) Full AcceSection The Company and its Subsidiaries will permit
representatives of the Buyer to have full access at all reasonable times, and in
a manner so as not to interfere with the normal business operations of the
Company and its Subsidiaries, to all premises, properties, personnel, books,
records (including tax records), contracts, and documents of or pertaining to
each of the Company and its Subsidiaries. The Buyer will treat and hold as such
any Confidential Information it receives from any of the Sellers, the Company,
and its Subsidiaries in the course of the reviews contemplated by this Section
5(d), will not use any of the Confidential Information except in connection with
the transactions contemplated hereby and, if this Agreement is terminated for
any reason whatsoever, will return to the Company and its Subsidiaries or
destroy all tangible embodiments (and all copies) of the Confidential
Information which are in its possession, all in accordance with the provisions
of that certain confidentiality agreement between Buyer and the Company, dated
as of May 25, 1999.
(e) Notice of Developments.
(i) The Company or Sellers may elect at any time to notify the
Buyer of any development causing a breach of any of the representations
15
and warranties in Section 4 above. No disclosure by the Company or
Sellers pursuant to this Section 5(e)(i), however, shall be deemed to
amend or supplement the Disclosure Schedule or to prevent or cure any
misrepresentation or breach of warranty.
(ii) Buyer may elect at any time to notify the Company and the
Sellers of any development causing a breach of any of the
representations and warranties in Section 3 above. No disclosure by the
Buyer pursuant to this Section 5(e)(ii), however, shall be deemed to
amend or supplement Annex I or to prevent or cure any misrepresentation
or breach of warranty.
(f) Exclusivity. None of the Sellers will (and the Sellers will not
cause or permit any of the Company and its Subsidiaries to) solicit, initiate,
or encourage the submission of any proposal or offer from any Person relating to
the acquisition of all or substantially all of the capital stock or assets of
any of the Company and its Subsidiaries (including any acquisition structured as
a merger, consolidation, or share exchange). Each of the Sellers acknowledges
and agrees that the Buyer would be damaged irreparably in the event this Section
5(f) is breached. Accordingly, notwithstanding anything herein to the contrary,
each of the Sellers agrees that the Buyer shall be entitled to an injunction or
injunctions to prevent breaches of and specifically enforce this Section 5(f).
(g) Amendment of Certain Agreements. Each of the Parties hereto
acknowledge and agree that (i) certain letter agreements relating to the
employment of ▇▇▇▇▇▇▇ ▇▇▇▇▇ and ▇▇▇ ▇▇▇▇▇ shall be amended in connection with
the Closing, pursuant to which each such Person shall be issued a certain number
of Common Shares and be entitled to such Person's portion of the Purchase Price
set forth on the Schedule of the Purchase Price Allocation, (ii) the Company's
stock appreciation program shall be amended and terminated in connection with
the Closing, pursuant to which the Company shall pay, and the Sellers shall
reimburse the Company for, the aggregate amounts (other than applicable payroll
taxes except Medicare taxes) required thereunder to be paid to the participants
in such program as set forth in Section 7(a)(ix) below, (iii) the management
agreement between ▇▇▇▇▇ Sundown, LLC and the Company shall be terminated in
connection with the Closing, (iv) the stock purchase and indemnification
agreement dated as of November 30, 1998, as amended, among Dr. A. ▇▇▇▇▇
▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇ and the Subsidiaries shall
be amended in connection with the Closing to remove the Subsidiaries as parties
thereto and (v) a certain shareholders agreement among the Sellers and the
Company shall be terminated in connection with the Closing.
6 Post-Closing Covenants.
(a) General. In case at any time after the Closing any further action
is necessary to carry out the purposes of this Agreement, each of the Parties
will take such further action (including the execution and delivery of such
further instruments and documents) as any other Party reasonably may request,
all at the sole cost and expense of the requesting Party. The Sellers
acknowledge and agree that from and after the Closing the Buyer will be entitled
to possession of all documents, books, records (including tax records),
agreements, and financial data of any sort relating to the Company and its
Subsidiaries.
(b) Covenant Not to Compete.
(i) Each of Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ and ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇ and
each of TSG2 Management, LLC and TSG3 Management, LLC on behalf of
itself and each investment fund of which it (or its Affiliate) serves
as the general partner or managing member (including TSG2 L.P. and TSG3
L.P.) hereby covenants and agrees that such Person, without the prior
written consent of Buyer, shall not for a period of one year (three
years with respect to Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇) from and after the Closing
Date, directly or indirectly, for itself or for any other person, firm,
corporation, partnership, association, or other entity, employ or
attempt to employ any employee of the Company or Buyer or any of
Buyer's Affiliates until at least six months after the date such
employee was not employed by the Company or the Buyer or any of Buyer's
Affiliates, as the case may be.
16
(ii) Each of Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇ and
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇ hereby covenants and agrees that such Person,
without the prior written consent of the Buyer, shall not for a period
of three years, one year and one year, respectively, from and after the
Closing Date: (A) directly or indirectly acquire or own in any manner
any interest in any person, firm, partnership, corporation,
association, or other entity which engages in any facet of the business
of the Company as of the Closing Date or as planned or budgeted for as
of the Closing Date (the "Business") or which competes in any way with
the business of Buyer or any of its Subsidiaries or Affiliates as of
the Closing Date, anywhere in the United States (the "Territory"), or
(B) be employed by or serve as an employee, agent, officer, director
of, or as a consultant to, any person, firm, partnership, corporation,
association, or other entity which engages in any facet of the Business
or which competes in any way with the business of Buyer or any of its
Subsidiaries or Affiliates as of the Closing Date within the Territory.
The ownership or control of up to one percent of the outstanding voting
securities or securities of any class of a company with a class of
securities registered under the Securities Exchange Act of 1934, as
amended, shall not be deemed a violation of this Section 6(b)(ii).
(iii) Each of TSG2 Management, LLC and TSG3 Management, LLC on
behalf of itself and each investment fund of which it (or its
Affiliate) serves as the general partner or managing member (including
TSG2 L.P. and TSG3 L.P.) hereby covenants and agrees that such Person,
without the prior written consent of the Buyer, shall not for a period
of one year from and after the Closing Date: (A) directly or indirectly
acquire or own in any manner any interest in any entity listed on
Section 6(b) of the Disclosure Schedule, or (B) be employed by or serve
as an employee, agent, officer, director of, or as a consultant to, any
entity listed on Section 6(b) of the Disclosure Schedule. The ownership
or control of up to one percent of the outstanding voting securities or
securities of any class of a company with a class of securities
registered under the Securities Exchange Act of 1934, as amended, shall
not be deemed a violation of this Section 6(b)(iii).
(iv) Nothing in this Section 6(b) shall be construed as
limiting or restricting (A) the ability to sell, in part or in whole,
any portfolio company of any investment fund of which either TSG2
Management, LLC or TSG3 Management, LLC (or another entity having the
same members as TSG2 Management, LLC or TSG3 Management, LLC) serves as
the general partner or managing member to any of the entities listed on
Section 6(b) of the Disclosure Schedule, whether for cash or non-cash
consideration (including, without limitation, equity securities of any
such entity listed on Section 6(b) of the Disclosure Schedule) or (B)
the ability of any member, partner or officer of either TSG2
Management, LLC or TSG3 Management, LLC (or another entity having the
same members as TSG2 Management, LLC or TSG3 Management, LLC) to serve
as a director, officer or consultant to any such entity listed on
Section 6(b) of the Disclosure Schedule in connection with any such
sale to such entity.
(v) Nothing in this Section 6(b) shall be construed as
limiting or restricting the ability of Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ from
engaging in any public speaking or writing (including speaking or
writing about health and nutrition issues), so long as the same is not
specifically designed to promote competing products or competing
companies, or in medical practice or research.
(c) Employee Bonuses. In connection with the Closing, with respect to
employees of the Company and its Subsidiaries, the Company shall pay at Closing,
and to the extent not paid at Closing, Buyer shall pay, or cause the Company to
pay, such bonuses of such employees which are accrued on the Financial
Statements of the Company and its Subsidiaries in accordance with the terms of
such bonus arrangements in an aggregate amount not to exceed $900,100 pursuant
to the schedule of such bonus arrangements previously delivered to Buyer.
17
7 Conditions to Obligation to Close.
(a) Conditions to Obligation of the Buyer and the Transitory
Subsidiary. The obligation of each of the Buyer and the Transitory Subsidiary to
consummate the transactions to be performed by it in connection with the Closing
is subject to satisfaction of the following conditions:
(i) the representations and warranties set forth in Section
3(a) and Section 4 above shall be true and correct in all material
respects at and as of the Closing Date;
(ii) the Company and the Sellers shall have performed and
complied with all of their covenants hereunder in all material respects
through the Closing;
(iii) there shall not be any injunction, judgment, order,
decree, ruling, or charge in effect preventing consummation of any of
the transactions contemplated by this Agreement;
(iv) the Company and the Sellers shall have delivered to the
Buyer a certificate to the effect that each of the conditions specified
above in Section 7(a)(i)-(iii) is satisfied in all respects;
(v) all applicable waiting periods (and any extensions
thereof) under the ▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Act shall have expired or
otherwise been terminated and the Parties, the Company, and its
Subsidiaries shall have received all other material authorizations,
consents, and approvals of governments and governmental agencies
referred to in Section 3(b) and Section 4(c) above;
(vi) the Buyer shall have received the resignations of (a)
each director of the Company and its Subsidiaries (as a director) and
(b) each officer of the Company and its Subsidiaries (as an officer)
who Buyer requests resign in a writing delivered at least five (5)
business days prior to the Closing, such resignations to be delivered
at and effective only upon the Closing (with the understanding that
such resignations shall not be deemed a breach of any employment
arrangement or fiduciary duty by any party);
(vii) the Buyer shall have received from counsel to the
Company and the Sellers an opinion addressed to the Buyer and dated as
of the Closing Date, in a form to be reasonably agreed to by counsels
for the respective Parties;
(viii) Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ shall have executed the
employment agreement in form and substance as set forth in Exhibit A
attached hereto, providing for the continued employment of Dr. A. ▇▇▇▇▇
▇▇▇▇▇▇▇▇ with the Buyer and the right of the Buyer to utilize, for
commercial purposes, his image, likeness, persona, and voice;
(ix) simultaneously in connection with the Closing, the
Company shall pay, and the Sellers shall reimburse the Company for, the
aggregate amounts (other than applicable payroll taxes except Medicare
taxes) required under the Company's stock appreciation program to be
paid to the participants in such program upon the consummation of the
transactions contemplated hereby (of which certain amounts shall be
subject to hold-back pursuant to a certain agreement among the Sellers
and such participants relating to the indemnification obligations of
the Sellers pursuant to this Agreement) and such stock appreciation
program shall be terminated without any liability to the Buyer;
(x) there shall not have been any material adverse change in
the business, financial condition, operations, assets or results of
operations of the Company and its Subsidiaries, taken as a whole;
provided, however, a decrease in net sales in an amount up to
$3,000,000 in each of December 1999 and January 2000 compared to the
projected net sales for each such month as previously provided in
18
writing to the Buyer shall not be considered to constitute such a
material adverse change; and
(xi) all actions to be taken by the Company and the Sellers in
connection with consummation of the transactions contemplated hereby
and all certificates, opinions, instruments, and other documents
required to effect the transactions contemplated hereby will be
reasonably satisfactory in form and substance to the Buyer and the
Transitory Subsidiary.
The Buyer and the Transitory Subsidiary may waive any condition specified in
this Section 7(a) if they execute a writing so stating at or prior to the
Closing.
(b) Conditions to Obligation of the Company and the Sellers. The
obligation of each of the Company and the Sellers to consummate the transactions
to be performed by them in connection with the Closing is subject to
satisfaction of the following conditions:
(i) the representations and warranties set forth in Section
3(b) above shall be true and correct in all material respects at and as
of the Closing Date;
(ii) the Buyer and the Transitory Subsidiary shall have
performed and complied with all of its covenants hereunder in all
material respects through the Closing;
(iii) there shall not be any injunction, judgment, order,
decree, ruling, or charge in effect preventing consummation of any of
the transactions contemplated by this Agreement;
(iv) the Buyer and the Transitory Subsidiary shall have
delivered to the Company and the Sellers a certificate to the effect
that each of the conditions specified above in Section 7(b)(i)-(iii) is
satisfied in all respects;
(v) all applicable waiting periods (and any extensions
thereof) under the ▇▇▇▇-▇▇▇▇▇- ▇▇▇▇▇▇ Act shall have expired or
otherwise been terminated and the Parties, the Company, and its
Subsidiaries shall have received all other material authorizations,
consents, and approvals of governments and governmental agencies
referred to in Section 3(b) and Section 4(c) above;
(vi) the Company and the Sellers shall have received from
counsel to the Buyer and the Transitory Subsidiary an opinion addressed
to the Sellers and dated as of the Closing Date, in a form to be
reasonably agreed to by counsels for the respective Parties;
(vii) concurrently with the Closing, Buyer shall pay the
Indebtedness of the Company (including amounts required to be paid to
the lenders in connection with the prepayment of such Indebtedness);
(viii) Buyer shall have executed the employment agreement in
form and substance as set forth in Exhibit B attached hereto, providing
for the continued employment of Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ with the Buyer
and the right of the Buyer to utilize, for commercial purposes, his
image, likeness, persona, and voice; and
(ix) all actions to be taken by the Buyer and the Transitory
Subsidiary in connection with consummation of the transactions
contemplated hereby and all certificates, opinions, instruments, and
other documents required to effect the transactions contemplated hereby
will be reasonably satisfactory in form and substance to the Company
and the Sellers.
The Company and the Sellers may waive any condition specified in this Section
7(b) if they execute a writing so stating at or prior to the Closing.
19
8. Remedies for Breaches of this Agreement.
(a) Survival of Representations and Warranties. All of the
representations and warranties contained herein shall survive the Closing
hereunder and continue in full force and effect for a period of one year
thereafter; provided, however, to the extent that a claim arises under the
representations and warranties contained herein that the Company has an
unreserved Tax obligation based on a claim that any Subsidiary's S corporation
election was invalid or had been terminated prior to January 5, 1999 ("S Tax
Claim"), then as to the representation and warranty concerning Taxes as they
relate to such S Tax Claim, the survival period shall be the applicable statute
of limitations for such S Tax Claim.
(b) Indemnification Obligations of All Sellers for Benefit of the
Buyer. In the event the Sellers breach any of their representations, warranties,
and covenants contained herein (other than the representation and warranty
concerning Taxes as they relate to any S Tax Claim) within the applicable
survival period pursuant to Section 8(a) above, provided that the Buyer makes a
written claim for indemnification against the Sellers pursuant to Section 11(g)
below within such survival period, then each of the Sellers shall indemnify the
Buyer from and against his or its Allocable Portion of any Adverse Consequences
the Buyer shall incur through and after the date of the claim for
indemnification caused proximately by such breach.
(c) Indemnification Obligations of Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇.
(x) For matters disclosed under sections I, II, III and IV of
Section 4(s) of the Disclosure Schedule and any other actions arising
from the same facts and circumstances (including, without limitation,
any claim of the Company or its Subsidiaries against Fireman's Fund or
any other insurer) (the "Foundation Litigation"), provided that the
Buyer makes a written claim for indemnification against Dr. A. ▇▇▇▇▇
▇▇▇▇▇▇▇▇ pursuant to Section 11(g) below, then Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
shall indemnify the Buyer from and against any Adverse Consequences the
Buyer shall incur caused by the Foundation Litigation. Notwithstanding
anything in this Agreement to the contrary, Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ shall
be entitled to control the Foundation Litigation (including the right
to bring or defend any action, prosecute or appeal any action and/or
settle any action) and shall bear all expenses in connection therewith.
The Buyer and the Company and its Subsidiaries shall cooperate with Dr.
A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ in handling such Foundation Litigation. In the event
that the Company or any of its Subsidiaries recovers any amounts in
such Foundation Litigation (including, without limitation, settlement
amounts, judgments for damages, insurance proceeds, reimbursement of
legal fees and costs, etc.) (the "Recovered Monies"), all such amounts
shall be promptly distributed to Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ and Buyer and
Company and its Subsidiaries shall not be entitled to any portion of
the Recovered Monies. Each of the Parties hereto (including, without
limitation, Buyer and Company and its Subsidiaries) agree that ▇▇▇▇▇ &
▇▇▇▇▇, current counsel for the Company and its Subsidiaries on the
Foundation Litigation and counsel for Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, may
continue to represent the Company and its Subsidiaries in the
Foundation Litigation and further acknowledge and agree to be bound by
all of the terms of that certain ▇▇▇▇▇ and ▇▇▇▇▇ waiver of conflict
letter dated November 25, 1998. The Buyer agrees to execute a similar
letter at the Closing. The indemnification obligations under this
Section 8(c)(i) shall survive the Closing indefinitely.
(xi) Pursuant to Section 8(c)(i) above, in the event that Dr.
A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ pays or indemnifies the Company for any amount of a
judgment or settlement in any of the Foundation Litigation in favor of
the Met-Rx Foundation (the "Foundation") and the judgment or settlement
requires that the Foundation use all or a portion of the amounts which
Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ pays to perform (through accredited research
facilities chosen by or reasonably acceptable to the Company) (a)
research on the efficacy of Company's products or (b) other research
20
requested or approved by the Company, the Company shall repay Dr. A.
▇▇▇▇▇ ▇▇▇▇▇▇▇▇ (as such money is used by the Foundation for such
research) the amounts spent by the Foundation on such research. By way
of example, if (a) the Company is required to pay $300,000 to the
Foundation, (b) Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ pays such amount under the
indemnification obligations of Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ under Section
8(c)(i) above and (c) the Foundation uses $250,000 to pay for research
on Company's products, then Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ would be entitled to
a repayment from the Company of $250,000 at the time the Foundation
pays for the research.
(xii) In the event there is a breach of the representation and
warranty concerning Taxes as they relate to any S Tax Claim within the
applicable survival period pursuant to Section 8(a) above, provided
that the Buyer makes a written claim for indemnification against Dr. A.
▇▇▇▇▇ ▇▇▇▇▇▇▇▇ pursuant to Section 11(g) below within such survival
period, then Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ shall indemnify the Buyer from and
against any Adverse Consequences the Buyer shall incur through and
after the date of the claim for indemnification caused proximately by
such breach.
(d) Limitations on Indemnification
(xiii) None of the Sellers shall have any obligation to
indemnify the Buyer from and against any Adverse Consequences pursuant
to Section 8(b) above, until the Buyer has incurred Adverse
Consequences by reason of all such breaches in excess of a $1,000,000
aggregate threshold, at which point each of the Sellers will be
obligated to indemnify the Buyer from and against his or its Allocable
Portion of such Adverse Consequences relating back to the first dollar.
(xiv) Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ shall have no obligation to
indemnify the Buyer from and against any Adverse Consequences pursuant
to Section 8(c)(i) above, until the Buyer has incurred Adverse
Consequences by reason of such Foundation Litigation in excess of a
$250,000 aggregate deductible, at which point Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
will be obligated to indemnify the Buyer from and against all such
Adverse Consequences in excess of $250,000.
(xv) To the extent the Buyer may have a claim for
indemnification pursuant to the provisions of Section 8(b) above for
any breach of any representation set forth in Section 4(o) or Section
4(q), the Buyer shall not be entitled to any indemnification under
Section 8(b) above until the Buyer gives credit for the amount of any
excess reserves for inventory and bad debts on the balance sheet as of
December 31, 1999 prepared by the Sellers and reasonably approved by
the Buyer in connection with the Closing (such credit to be given by
reducing dollar for dollar the amount of any Adverse Consequences
resulting from a breach of any representation set forth in Section 4(o)
or Section 4(q) by the aggregate amount of any and all excess reserves
for inventory and bad debts set forth on such balance sheet).
(xvi) The aggregate amount of all the Sellers' liability under
Section 8(b) above and Section 8(c)(iii) above shall not exceed
$5,400,000 and the maximum liability under Section 8(b) above for any
particular Seller shall be such Seller's Allocable Portion of
$5,400,000.
(xvii) Notwithstanding the foregoing provisions of this
Section 8(d), the $1,000,000 threshold and $5,400,000 "cap" limitations
on indemnification obligations set forth in Section 8(d)(i) above and
Section 8(d)(iv) above, respectively, shall not apply to any failure to
comply with the agreements set forth in Section 5(g) above and Section
7(a)(ix) above.
(e) Indemnification Provisions for Benefit of the Sellers. In the event
the Buyer breaches any of its representations, warranties, and covenants
contained herein within the applicable survival period pursuant to Section 8(a)
above, provided that any of the Sellers makes a written claim for
indemnification against the Buyer pursuant to Section 11(g) below within such
survival period, then the Buyer agrees to indemnify each of the Sellers from and
against the entirety of any Adverse Consequences the Seller shall incur through
and after the date of the claim for indemnification caused proximately by the
breach.
(f) Matters Involving Third Parties.
21
(i) If any third party shall notify any Party (the
"Indemnified Party") with respect to any matter (a "Third Party Claim")
which may give rise to a claim for indemnification against any other
Party (the "Indemnifying Party") under this Section 8, then the
Indemnified Party shall promptly (and in any event within five business
days after receiving notice of the Third Party Claim) notify each
Indemnifying Party thereof in writing; provided, however, that no delay
on the part of the Indemnified Party in notifying any Indemnifying
Party shall relieve the Indemnifying Party from any obligation
hereunder unless (and then solely to the extent) the Indemnifying Party
thereby is prejudiced.
(ii) Any Indemnifying Party will have the right at any time to
assume and thereafter conduct the defense of the Third Party Claim with
counsel of his or its choice reasonably satisfactory to the Indemnified
Party; provided, however, that the Indemnifying Party will not consent
to the entry of any judgment or enter into any settlement with respect
to the Third Party Claim without the prior written consent of the
Indemnified Party (not to be withheld unreasonably) unless the judgment
or proposed settlement involves only the payment of money damages, does
not impose an injunction or other equitable relief upon the Indemnified
Party, does not impose any restrictions on the operation of the Company
and its Subsidiaries and, together with any other judgment or
settlement the Indemnifying Party has consented to or entered into
pursuant to this Section 8, does not in the aggregate exceed
$5,400,000; provided, further, in the event an Indemnifying Party
assumes the defense of the Third Party Claim as provided above, the
Indemnified Party may (a) retain separate co-counsel at its sole cost
and expense and participate in the defense of the Third Party Claim and
(b) assume complete control and thereafter conduct the defense of the
Third Party Claim once the Indemnifying Party has no further
indemnification obligations hereunder.
(iii) Unless and until an Indemnifying Party assumes the
defense of the Third Party Claim as provided in Section 8(f)(ii) above,
however, the Indemnified Party may defend against the Third Party Claim
in any manner he or it reasonably may deem appropriate.
(iv) Unless and until an Indemnifying Party assumes the
defense of the Third Party Claim as provided in Section 8(f)(ii) above,
in no event will the Indemnified Party consent to the entry of any
judgment or enter into any settlement with respect to the Third Party
Claim without the prior written consent of each of Dr. A. ▇▇▇▇▇
▇▇▇▇▇▇▇▇, TSG2 L.P. and TSG3 L.P. (not to be withheld unreasonably).
(g) Determination of Adverse Consequences. The Parties shall make
appropriate adjustments for tax benefits and insurance recovery in determining
Adverse Consequences for purposes of this Section 8. All indemnification
payments under this Section 8 shall be deemed adjustments to the Purchase Price.
(h) Exclusive Remedy. The Buyer and the Sellers acknowledge and agree
that after the Closing the foregoing indemnification provisions in this Section
8 shall be the exclusive remedy of the Buyer and the Sellers with respect to the
Company and its Subsidiaries.
9. Tax Matters.
(a) Certain Taxes. All transfer, documentary, sales, use, stamp,
registration and other similar taxes and fees (including any penalties and
interest) incurred in connection with this Agreement shall be paid by Sellers
when due, and Sellers will, at their own expense, file all necessary tax returns
and other documentation with respect to all such transfer, documentary, sales,
use, stamp, registration and other taxes and fees, and, if required by
applicable law, Buyer will, and will cause its affiliates to, join in the
execution of any such tax returns and other documentation.
(b) Myosystems Deduction Deferral. To the extent of the net tax benefit
resulting from any requirement by the California Franchise Tax Board to amortize
22
over a longer period of years and defer the allowable tax deduction in
connection with a certain buy-out by the Company of a distribution agreement
relating to Myosystems, the Buyer shall pay to Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ such amount
in each year the Company and its Subsidiaries take such a tax deduction.
Notwithstanding anything herein to the contrary, if as a result of a
determination under the audit of such issue that the Company must defer such
deductions, the Company owes additional Taxes, Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ shall be
liable for reimbursing such amounts to the Company (offset by any payment owing
to Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ under this Section 9(b)). Dr. A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ shall
be liable for all costs and expenses in connection with such an audit.
10. Termination.
(a) Termination of Agreement. Certain of the Parties may terminate this
Agreement as provided below:
(v) the Parties may terminate this Agreement by mutual written
consent at any time prior to the Closing;
(vi) the Buyer and the Transitory Subsidiary may terminate
this Agreement by giving written notice to the Company and the Sellers
at any time prior to the Closing (a) (i) in the event any of the
Company or the Sellers have breached any material representation,
warranty, or covenant contained in this Agreement in any material
respect, (ii) the Buyer has become aware of the breach and has notified
the Sellers within 5 days of becoming aware of such breach of Buyers'
intent to terminate the Agreement unless such breach is cured within 30
days of such notice, and (iii) the breach has continued without cure
for such 30-day period, or (b) if the Closing shall not have occurred
on or before January 31, 2000, by reason of the failure of any
condition precedent under Section 7(a) hereof (unless the failure
results primarily from the Buyer or the Transitory Subsidiary breaching
any representation, warranty, or covenant contained in this Agreement);
provided, however, if the Closing shall not have occurred on or before
January 31, 2000 by reason of failure to comply with the requirements
of the ▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Act or due to a "second request" being made by
the Justice Department and the applicable waiting periods thereunder
have not expired (so long as the initial and "second request" filings
required thereunder were filed within 7 days of the date hereof and the
date of the "second request," respectively), the Buyer and the
Transitory may not terminate this Agreement under clause (b) above
until February 28, 2000; and
(vii) the Company and the Sellers may terminate this Agreement
by giving written notice to the Buyer at any time prior to the Closing
(a) (i) in the event any of the Buyer or the Transitory Subsidiary have
breached any material representation, warranty, or covenant contained
in this Agreement in any material respect, (ii) the Company or the
Sellers have become aware of the breach and have notified the Buyer
within 5 days of becoming aware of such breach of the Company and the
Sellers' intent to terminate the Agreement unless such breach is cured
within 30 days of such notice, and (iii) the breach has continued
without cure for such 30-day period, or (b) if the Closing shall not
have occurred on or before January 31, 2000, by reason of the failure
of any condition precedent under Section 7(b) hereof (unless the
failure results primarily from any of the Company or the Sellers
themselves breaching any representation, warranty, or covenant
contained in this Agreement); provided, however, if the Closing shall
not have occurred on or before January 31, 2000 by reason of failure to
comply with the requirements of the ▇▇▇▇-▇▇▇▇▇-▇▇▇▇▇▇ Act or due to a
"second request" being made by the Justice Department and the
applicable waiting periods thereunder have not expired (so long as the
initial and "second request" filings required thereunder were filed
within 7 days of the date hereof and the date of the "second request,"
respectively), the Company and the Sellers may not terminate this
Agreement under clause (b) above until February 28, 2000.
(b) Effect of Termination. If any Party terminates this Agreement
pursuant to Section 10(a) above, all rights and obligations of the Parties
23
hereunder shall terminate without any liability of any Party to any other Party
(except for any liability of any Party then in breach); provided, however, that
the confidentiality provisions contained in Section 5(d) and the confidentiality
agreement referred to in Section 5(d) above shall survive termination.
11. Miscellaneous.
(a) Press Releases and Public Announcements. No Party shall issue any
press release or make any public announcement relating to the subject matter of
this Agreement prior to the Closing without the prior written approval of the
other Parties hereto; provided, however, that any Party may make any public
disclosure it believes in good faith is required by applicable law or any
listing or trading agreement concerning its publicly-traded securities (in which
case the disclosing Party will use its reasonable best efforts to advise the
other Parties prior to making the disclosure).
(b) No Third-Party Beneficiaries. This Agreement shall not confer any
rights or remedies upon any Person other than the Parties and their respective
successors and permitted assigns.
(c) Entire Agreement. This Agreement (including the documents referred
to herein) constitutes the entire agreement among the Parties and supersedes any
prior understandings, agreements, or representations by or among the Parties,
written or oral, to the extent they related in any way to the subject matter
hereof.
(d) Succession and Assignment. This Agreement shall be binding upon and
inure to the benefit of the Parties named herein and their respective successors
and permitted assigns. No Party may assign either this Agreement or any of his
or its rights, interests, or obligations hereunder without the prior written
approval of the Buyer and the Sellers.
(e) Counterparts. This Agreement may be executed in one or more
counterparts, each of which shall be deemed an original but all of which
together will constitute one and the same instrument.
(f) Headings. The section headings contained in this Agreement are
inserted for convenience only and shall not affect in any way the meaning or
interpretation of this Agreement.
(g) Notices. All notices, requests, demands, claims, and other
communications hereunder will be in writing. Any notice, request, demand, claim,
or other communication hereunder shall be deemed duly given if (and then two
business days after) it is sent by registered or certified mail, return receipt
requested, postage prepaid, and addressed to the intended recipient as set forth
below:
If to the Company A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, M.D.
or the Sellers: c/o Krane & ▇▇▇▇▇
▇▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇ ▇▇▇▇▇, Esq.
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
TSG2 L.P.
TSG3 L.P.
c/o The Shansby Group
▇▇▇ ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇ ▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
With respect to any other Seller, to
the address and/or facsimile number
24
set forth beside the name of such
Seller on the Schedule of Sellers.
Copy to: ▇▇▇▇▇▇▇▇ & ▇▇▇▇▇
▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇ ▇. ▇▇▇▇▇, Esq.
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
If to the Buyer: Rexall Sundown, Inc.
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇.▇.
▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇ ▇▇▇▇▇▇, Chief Financial Officer
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
Copy to: Rexall Sundown, Inc.
▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇ ▇▇▇▇▇▇▇, ▇.▇.
▇▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇▇▇▇ ▇▇▇▇▇▇, General Counsel
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
and a copy to: ▇▇▇▇▇▇▇▇▇ Traurig, P.A.
▇▇▇▇ ▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇
Attention: ▇▇▇▇ ▇▇▇▇▇▇▇▇▇, Esq.
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
Any Party may send any notice, request, demand, claim, or other communication
hereunder to the intended recipient at the address set forth above using any
other means (including personal delivery, expedited courier, messenger service,
telecopy, telex, ordinary mail, or electronic mail), but no such notice,
request, demand, claim, or other communication shall be deemed to have been duly
given unless and until it actually is received by the intended recipient. Any
Party may change the address to which notices, requests, demands, claims, and
other communications hereunder are to be delivered by giving the other Parties
notice in the manner herein set forth.
(h) Governing Law. This Agreement shall be governed by and construed in
accordance with the domestic laws of the State of California without giving
effect to any choice or conflict of law provision or rule (whether of the State
of California or any other jurisdiction) that would cause the application of the
laws of any jurisdiction other than the State of California.
(i) Amendments and Waivers. No amendment of any provision of this
Agreement shall be valid unless the same shall be in writing and signed by the
Parties hereto. No waiver by any Party of any default, misrepresentation, or
breach of warranty or covenant hereunder, whether intentional or not, shall be
deemed to extend to any prior or subsequent default, misrepresentation, or
breach of warranty or covenant hereunder or affect in any way any rights arising
by virtue of any prior or subsequent such occurrence.
(j) Severability. Any term or provision of this Agreement that is
invalid or unenforceable in any situation in any jurisdiction shall not affect
the validity or enforceability of the remaining terms and provisions hereof or
the validity or enforceability of the offending term or provision in any other
situation or in any other jurisdiction.
(k) Expenses. Except as otherwise provided herein, each of the Buyer,
the Transitory Subsidiary, the Company, and the Company's Subsidiaries will bear
its own costs and expenses (including legal fees and expenses) incurred in
connection with this Agreement and the transactions contemplated hereby. The
25
Company will also bear all of the Sellers' costs and expenses (including all of
their legal fees and expenses) incurred in connection with this Agreement and
the transactions contemplated hereby (other than any Tax imposed on the Sellers
on any gain resulting from the sale of the Shares hereunder) and there shall be
no reduction in the Purchase Price as a result of such bearing of such costs and
expenses. Notwithstanding anything herein to the contrary, (i) the Company and
its Subsidiaries (and not the Sellers) shall bear any fees payable to Lazard
Freres & Co. LLC and its Affiliates with respect to the transactions
contemplated by this Agreement (pursuant to a certain engagement letter dated as
of July 28, 1999) and there shall be no reduction in the Purchase Price due to
such liability and (ii) TSG2 L.P. and TSG3 L.P. (and not the Company and its
Subsidiaries and the other Sellers) shall bear any fees payable to ▇▇▇▇▇▇▇▇▇,
▇▇▇▇▇▇ & ▇▇▇▇▇▇▇▇ and its Affiliates with respect to the transactions
contemplated by this Agreement.
(l) Construction. The Parties have participated jointly in the
negotiation and drafting of this Agreement. In the event an ambiguity or
question of intent or interpretation arises, this Agreement shall be construed
as if drafted jointly by the Parties and no presumption or burden of proof shall
arise favoring or disfavoring any Party by virtue of the authorship of any of
the provisions of this Agreement. Any reference to any federal, state, local, or
foreign statute or law shall be deemed also to refer to all rules and
regulations promulgated thereunder, unless the context requires otherwise. The
word "including" shall mean including without limitation.
(m) Waiver of Jury Trial. EACH PARTY HERETO HEREBY WAIVES ITS RIGHTS TO
A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION BASED UPON OR ARISING OUT OF THIS
AGREEMENT, THE RELATED AGREEMENTS OR THE SUBJECT MATTER HEREOF OR THEREOF. THE
SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES
THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS
TRANSACTION, INCLUDING, WITHOUT LIMITATION, CONTRACT CLAIMS, TORT CLAIMS, BREACH
OF DUTY CLAIMS, AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THIS Section
11(M)(III) HAS BEEN FULLY DISCUSSED BY EACH OF THE PARTIES HERETO AND THESE
PROVISIONS SHALL NOT BE SUBJECT TO ANY EXCEPTIONS. EACH PARTY HERETO HEREBY
FURTHER REPRESENTS AND WARRANTS THAT SUCH PARTY HAS REVIEWED THIS WAIVER WITH
ITS LEGAL COUNSEL, AND THAT SUCH PARTY KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY
TRIAL RIGHTS FOLLOWING CONSULTATION WITH LEGAL COUNSEL. THIS WAIVER IS
IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING,
AND THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, SUPPLEMENTS OR
MODIFICATIONS TO (OR ASSIGNMENTS OF) THIS AGREEMENT. IN THE EVENT OF LITIGATION,
THIS AGREEMENT MAY BE FILED AS WRITTEN CONSENT TO A TRIAL (WITHOUT JURY) BY THE
COURT.
(n) Indemnification of Directors and Officers; Insurance.
(viii) The Buyer shall cause the Company and its Subsidiaries
to not, amend, repeal or otherwise modify the provisions with respect
to indemnification set forth in the charter and the bylaws of the
Company and its Subsidiaries as in effect on the day prior to the
Closing Date, in any manner that would adversely affect the rights
thereunder of individuals who on or prior to the Closing Date were
directors, officers, employees or agents of the Company and its
Subsidiaries, unless such modification is required by law (and then
only to the minimum extent required by law).
(ix) The Buyer shall, at its own expense, purchase and
maintain in effect not less than five years from the Closing Date,
policies of directors' and officers' liability and fiduciary insurance,
on terms with respect to coverage and amount substantially consistent
with the Company's current directors' and officers' liability and
insurance, pursuant to which the Company's current directors and
officers will be insured with respect to claims arising from the facts
or events occurring on or prior to the Closing Date; provided, however,
26
in no event shall the Buyer be required to pay premiums per annum in an
amount exceeding 120% of the current annual premiums under the
Company's current directors' and officers' liability insurance;
provided, further, in the event such premiums would exceed such 120%
threshold in any effective year of this obligation, Buyer (a) shall
afford the Sellers the opportunity to contribute the balance of the
cost of such insurance exceeding such 120% threshold amount and (b) if
the Sellers decline to make such contribution, shall, at its own
expense, purchase and maintain such policies of directors' and
officers' liability and fiduciary insurance obtainable for such 120%
threshold amount.
(o) Incorporation of Exhibits, Annexes, and Schedules. The Exhibits,
Annexes, and Schedules identified in this Agreement are incorporated herein by
reference and made a part hereof.
IN WITNESS WHEREOF, the Parties hereto have executed this Agreement as
of the date first above written.
REXALL SUNDOWN, INC.
By: /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
----------------------
Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Title: President
RSM ACQUISITION CORP.
By: /s/ ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
----------------------
Name: ▇▇▇▇▇ ▇▇▇▇▇▇▇▇
Title: President
TSG2 L.P., by its general partner
TSG2 Management, LLC
By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
---------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Title: Managing Member
TSG3 L.P., by its general partner
TSG3 Management, LLC
By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
---------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Title: Managing Member
▇▇▇▇▇▇▇▇ (1999) Limited Partnership,
by its general partner ▇▇▇▇▇▇▇▇
(1999) Company Inc.
By: /s/ ▇▇▇▇▇▇ ▇▇▇▇▇
--------------------
Name: ▇▇▇▇▇▇ ▇▇▇▇▇
Title: Assistant Secretary
27
A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, M.D.
/s/ A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, M.D.
---------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
------------------------
▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
/s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇▇
------------------------
▇▇▇▇▇▇▇ ▇▇▇▇▇
/s/ ▇▇▇▇▇▇▇ ▇▇▇▇▇
-----------------
▇▇▇ ▇▇▇▇▇
/s/ ▇▇▇ ▇▇▇▇▇
-------------
MET-Rx NUTRITION, INC.
By: /s/ A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, M.D.
-------------------------------
Name: A. ▇▇▇▇▇ ▇▇▇▇▇▇▇▇, M.D.
Title: Chief Technical Officer
Only for the purpose of acknowledging
and agreeing to Section 6(b) of this Agreement:
TSG2 Management, LLC
By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
---------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Title: Managing Member
TSG3 Management, LLC
By: /s/ ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
---------------------------
Name: ▇▇▇▇▇▇▇ ▇. ▇▇▇▇▇▇▇▇
Title: Managing Member
28